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Studies of potent antiretroviral combination regimens were undertaken in young infants to evaluate the
potential for long-term suppression of viral replication and to evaluate the immune consequences of such
therapies. Early combination antiretroviral therapy led to a loss of plasma viremia, cultivable virus, and labile
extrachromosomal replication intermediates. Despite preservation of immune function, persistent human
immunodeficiency type 1 (HIV-1)-specific immune responses were not detected in most infants. The absence of
detectable, persisting immune responses in most HIV-1-infected infants treated early contrasts with what is
typically seen in adults who are treated early. These results are consistent with the notion that early combi-
nation antiretroviral therapy of HIV-1-infected infants allows the long-term suppression of viral replication.
The integration of sensitive molecular techniques for the
measurement of viral nucleic acids into clinical trials evaluat-
ing potent antiretroviral therapies has allowed significant ad-
vances in our understanding of the pathogenesis of human
immunodeficiency virus type 1 (HIV-1) infection (reviewed in
reference 7). Data from such clinical trials in adults and chil-
dren suggest that HIV-1 replication plays a central role in the
pathogenesis of HIV-1 infection. Even in early vertical HIV-1
infection (i.e., the first few months of life), plasma viral turn-
over is extremely rapid (21), and early plasma HIV-1 viral load
appears to be predictive of subsequent disease course (1, 10).
In the macaque model of simian immunodeficiency virus in-
fection, the administration of antiretroviral therapy in early
acute infection interferes with the establishment of infection
(34, 35). It has therefore been suggested that controlling
HIV-1 replication through the use of early, potent combination
therapy regimens would provide the best opportunity to con-
trol viral replication and to preserve the immune system fol-
lowing vertical infection.
Data from the first trial of potent combination therapy in
early vertical infection suggested that long-term suppression of
HIV-1 replication was feasible (17). While the long-term sup-
pression of viral replication was associated with preservation of
the immune system, persistent HIV-1-specific immune re-
sponses were not detected following the suppression of viral
replication. Further studies of potent antiretroviral combina-
tion regimens were therefore undertaken in young infants to
better evaluate the potential for long-term suppression of viral
replication and to evaluate the immune consequences of such
therapies.
MATERIALS AND METHODS
Study population. These studies were conducted through the Pediatric AIDS
Clinical Trials Group (PACTG protocols 180 and 356). Plasma HIV-1 RNA
levels fell to ,50 copies/ml in 15 (62%) of 24 infants who initiated therapy at ,3
months of age through PACTG 356. We have also continued long-term fol-
low-up (50 months) of two infants from a prior early therapy study (17).
Infants were defined as infected and eligible for enrollment into one of these
protocols if HIV-1 nucleic acids were detected in peripheral blood lymphocytes
using PCR on at least one occasion and HIV-1 was subsequently isolated from
the peripheral blood mononuclear cells (PBMC). All infants studied were either
asymptomatic or only mildly symptomatic (Centers for Disease Control and
Prevention clinical category N, A, or B [6]). Individual patient characteristics and
antiretroviral regimens are outlined in Table 1.
The human subjects committees at the participating clinical sites approved
these studies. Written informed consent was obtained from the children’s legal
guardians. The guidelines of the U.S. Department of Health and Human Services
governing experimentation in humans were followed.
Preparation of plasma and PBMC for assays. Blood samples were collected in
evacuated specimen tubes containing either acid-citrate-dextrose or EDTA (Va-
cutainer; Becton-Dickinson, Mountainview, Calif.). Within 6 h of phlebotomy,
the specimen tubes were centrifuged at 1,500 3 g for 15 min. Following repeat
centrifugation of plasma at 1,500 3 g for 10 min at room temperature, the
supernatant was removed, divided into aliquots of 0.5 ml, and frozen promptly at
270°C. PBMC were recovered from the cell layer by Ficoll-Paque (Pharmacia,
Piscataway, N.J.) density centrifugation (3).
Quantification of plasma HIV-1 RNA copy number by reverse transcriptase
(RT)-mediated PCR. HIV-1 RNA was quantified in 200 ml of EDTA-anticoag-
ulated plasma (stored at 270°C within 6 h following phlebotomy) by PCR after
reverse transcription (Amplicor; Roche). Plasma samples with values below the
detection limit of the standard assay (,400 copies/ml) were subsequently tested
using 450 ml of plasma and a modified assay with a detection limit of 50 HIV-1
RNA copies/ml. All assays were performed in a single laboratory that partici-
pates in an ongoing quality certification program for HIV-1 RNA quantitation
sponsored by the National Institutes of Health.
Enumeration of lymphocyte subsets in the peripheral blood. The relative
percentages of CD31 CD41 lymphocytes in the peripheral blood were enumer-
ated using direct immunofluorescence with fluorescein isothiocyanate (FITC)- or
phycoerythrin-conjugated mouse monoclonal antibodies (Becton Dickinson).
Samples were analyzed using flow cytometry (Becton Dickinson FACScan).
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HIV-1 serology. Plasma HIV-1 immunoglobulin G antibodies were detected
using a commercial enzyme-linked immunosorbent assay (ELISA) (Vironostika
HIV-1 Microelisa system; Organon-Teknika, Durham, N.C.). Antibody specific-
ity was ascertained by Western blotting (Calyptebiomedical, Rockville, Md.).
Measurement of plasma immunoglobulins. Plasma immunoglobulin levels
were measured in the University of Massachusetts Medical Center clinical lab-
oratory.
Lymphoproliferative assays. Lymphoproliferative assays were performed by
the methods of Rosenberg et al. (30), except that the recombinant HIV-1 p24
and gp160 proteins were used at a final concentration of 5 mg/ml. Pokeweed
mitogen (PWM) (Sigma) was used at a concentration of 10 mg/ml. Tetanus
toxoid (Connaught) was used at 1.25 and 2.5 mg/ml. For the recombinant HIV-1
proteins, the stimulation index (SI) was defined as the ratio of the mean counts
per minute of the HIV-1 protein wells to the mean counts per minute of the
control protein wells. For PWM and tetanus toxoid, the SI was defined as the
ratio of the mean counts per minute of the stimulated wells to the mean counts
per minute of the stimulated wells to the mean counts per minute of the wells
containing cells and medium alone. Assays were considered valid only if the
counts per minute measured in each of the control wells (i.e., the control protein
wells and the wells containing cells and media alone) was less than 1,000.
Detection of HIV-1-specific CTL precursors following virus-specific in vitro
stimulation of PBMC. We (18, 28) have previously demonstrated the detection
of cytotoxic T-lymphocyte (CTL) precursors in viably cryopreserved PBMC from
infants who did not receive early, potent combination antiretroviral therapy.
Freshly isolated PBMC were viably cryopreserved using a KRYO 10 series cell
freezer and stored in liquid nitrogen until use. PBMC were used for these studies
only if their viability (determined by trypan blue exclusion) was greater than
90%. Cryopreserved patient PBMC (3 3 106 to 5 3 106) were thawed and
cultured with psoralen-fixed, autologous B-lymphoblastoid cell lines (B-LCL)
infected with a recombinant vaccinia virus expressing the HIV-1 gag, envelope,
and polymerase gene products (VT408; Therion Biologics, Cambridge, Mass.).
At 14 days, the resultant cell lines were tested for HIV-1-specific cytotoxicity
using autologous B-LCL infected with vaccinia virus or vaccinia virus recombi-
nant expressing HIV-1 gag (vABT 141) or env (vABT 299) gene products (18) in
a 51Cr release assay using an effector/target ratio of 50:1.
Detection and enumeration of HIV-1-specific CD81 T cells using HLA-peptide
tetramers. HLA A*0201 heavy chain and human b2-microglobulin in the pro-
caryotic expression system (pET R 1 D) were obtained from David Garboczi
(National Institutes of Health). The 39 end of the HLA A*0201 heavy chain was
modified by adding a Gly/Ser linker to amino acid (aa) 276 of the HLA sequence
followed by the BirA biotinylation site and a stop codon (2, 9). These expression
plasmids in XA-90 cells were grown to mid-log phase and induced with 0.5 mM
isopropyl-b-thiogalactosidase (IPTG). Inclusion bodies were purified as de-
scribed previously (13) and solubilized in 6 M guanidine-HCl (pH 8.2). The
heavy chain and b2-microglobulin were refolded with each of the following
peptides: the HIV-1 Gag p17 peptide (LAI aa 77 to 85; SLYNTVATL), the
HIV-1 RT peptide (LAI aa 476 to 484; ILKEPVHGV), or the Epstein-Barr virus
(EBV) BMLF1 peptide (aa 280 to 288/GLCTLVAML). Purified monomers were
biotinylated with BirA (Avidity, Denver, Colo.) overnight at 30°C and separated
from free biotin using Centricon-30 centrifugation concentrators. Biotinylated
monomers were mixed with Neutravidin–R-phycoerythrin conjugate (Sigma) at
a molar ratio of 4:1 to form tetramers (2).
Cryopreserved PBMC (106) from individual study participants were thawed
and stained with 1 ml of tetramer along with CD3-Cychrome and CD8-FITC
(Pharmingen, La Jolla, Calif.) and analyzed by flow cytometry. All available
samples from an individual study participant were stained and analyzed together.
A positive control (an epitope-specific, HLA A*0201-restricted CTL line) and
negative controls (PBMC from HIV-1-uninfected, HLA A*0201-positive indi-
viduals) were included in each assay. Tetramer staining of PBMC from HIV-1-
uninfected, HLA A*0201-positive individuals was always ,0.02%.
Detection of HIV-1 2-LTR circles in PBMC. PBMC pellets were resuspended
in buffer P1, and extrachromosomal DNA was purified by a QIAprep spin
miniprep kit (Qiagen, Valencia, Calif.), using the modification for the isolation
of low-copy-number plasmids as recommended by the manufacturer. Chromo-
somal DNA was recovered from the sodium acetate-sodium dodecyl sulfate
precipitate using DNAzol reagent (Life Technologies, Gaithersburg, Md.) ac-
cording to the manufacturer’s protocol. Total cellular DNA was purified using an
Isoquick nucleic acid extraction kit (ORCA Research, Bothell, Wash.). 2-LTR
(long terminal repeat) circle junctions were amplified from 10 to 30 ml of
extrachromosomal DNA in a 50-ml reaction containing 13 HotStarTaq buffer,
200 nM deoxynucleoside triphosphates, 400 nM primers, and 1.5 U of HotStar-
Taq (Qiagen). The reverse and forward primers were 59-cagatctggtctaaccagag
a-39 and 59-gtaactagagatccctcagac-39, which annealed to nucleotides 9157 to 9137
(HIV-1 LTR R region) and nucleotides 130 to 150 (HIV-1 LTR U5 region) of
HIV-1LAI, respectively (accession number K02013). After an initial denaturation
step (95°C, 10 min), PCR amplification proceeded for 45 cycles (95°C, 30 s; 60°C,
30 s; 72°C, 60 s) followed by a final extension (72°C, 5 min). To control for the
effect of sequence polymorphisms at primer binding sites, amplification was
performed with internal primers that were reversed in orientation to those listed
above. Amplification with the internal LTR primers proceeded for 35 cycles
using conditions outlined above. Polymorphisms in the region of the LTR that is
recognized by the fluorogenic probe can affect annealing of the probe and
potentially result in false negatives. To accommodate this, Taqman reaction
products were subsequently analyzed on agarose-Tris-borate-EDTA gels and
stained with ethidium bromide to ensure that those reactions did not contain
episome-specific PCR products. For quantitation of 2-LTR circle frequency in
patient PBMC, PCRs were performed using an ABI Prism 7700 sequence de-
tection system with the addition of 200 nM fluorogenic probe to the reaction
(59-agtggcgagccctcagatgctgc-39) which anneals to nucleotides 9081 to 9103 of
HIV-1LAI. The oligonucleotide probe was modified with 6-FAM (6-carboxyfluo-
rescein) reporter dye on the 59 end and 6-TAMRA (6-carboxytetramethylrho-
damine) quencher dye on the 39 end. Copy number estimates of 2-LTR circles
were determined either by extrapolation from a plot of standards versus band
intensity or by using the ABI Prism 7700 quantitation software.
RESULTS
Long-term suppression of plasma HIV-1 load following the
initiation of early combination antiretroviral therapy. These
studies focus on 17 HIV-1-infected infants who initiated open-
label, three- or four-drug antiretroviral regimens between 15
days and 3 months of age, with subsequent suppression of
TABLE 1. Characteristics of the study population
Patient Antiretroviral therapya Age(mo)
Baseline
plasma RNA
(log copies/ml)
Baseline
% CD4
Time (wk) to
RNA ,400
Length of
follow-up
(mo)
P-1048 ZDV/3TC/NVP 0.5 4.5 34 12 29
P-1216 ZDV/3TC/NVP 2.8 5.7 14 12 27
P-1228 ZDV/3TC/NVP 1.1 5.3 47 16 32
P-1232 ZDV/3TC/NVP/ABV 3.0 5.0 40 16 21
P-1235 ZDV/3TC/NVP/ABV 2.2 5.3 24 2 27
P-1238 ZDV/3TC/NVP/ABV 3.0 3.3 52 0.5 24
P-1246 ZDV/3TC/NVP/ABV 0.8 5.2 54 8 24
P-1247 ZDV/3TC/NVP/ABV 1.1 4.3 63 4 21
P-1222 d4T/3TC/NVP/NLF 1.8 5.5 36 16 18
P-1223 d4T/3TC/NVP/NLF 1.5 5.2 34 8 18
P-1231 d4T/3TC/NVP/NLF 1.7 5.8 52 16 16
P-1233 d4T/3TC/NVP/NLF 1.9 5.6 30 12 16
P-1251 d4T/3TC/NVP/NLF 2.2 5.2 19 8 18
P-1252 d4T/3TC/NVP/NLF 1.6 5.4 46 8 18
P-1260 d4T/3TC/NVP/NLF 2.4 5.2 55 12 18
P-3743 ZDV/ddI/NVP 2.5 5.5 44 8 56
P-3742 ZDV/ddI/NVP 2.5 5.5 57 20 56
a ABV, abacavir.
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plasma HIV-1 RNA levels to ,50 copies/ml. Individual patient
characteristics and treatment regimens are provided in Table 1.
Prior to the initiation of study drug therapy, plasma HIV-1
RNA copy numbers ranged from 103.3 to 105.8 copies (median,
105.3/ml [Table 1]). As described previously (21), a biphasic
clearance of HIV-1 virions from the plasma was observed fol-
lowing the initiation of antiretroviral therapy. An initial, rapid
exponential decline (median half-life 5 0.9 days) in plasma
HIV-1 virions was followed by a slower second phase decline
(median half-life 5 15 days). Over 90% of plasma virions were
cleared during the first phase of viral decay, and the plasma
HIV-1 RNA copy number fell below 400 copies/ml by 20 weeks
(range, 0.5 to 20 weeks; median, 12 weeks) in all infants.
An ultrasensitive assay was then used to detect and measure
plasma HIV-1 RNA copy numbers in subsequent plasma sam-
ples. Plasma HIV-1 RNA fell below 50 copies/ml in 13 infants
(76%) within 24 weeks of initiating therapy. By 40 weeks of
therapy, plasma HIV-1 RNA was ,50 copies/ml in all but one
infant; plasma HIV-1 RNA fell to ,50 copies/ml by 68 weeks
in that infant.
Intensive follow-up of these infants has continued through a
median of 21 months (range, 16 to 56 months [Table 1]). After
15 months of therapy, HIV-1 RNA (1,000 to 1,700 copies/ml)
was again detectable in the plasma of one infant (P-3742) (Fig.
1). Following a change in regimen from zidovudine (ZDV),
didanosine (ddI), and nevirapine (NVP) to stavudine (D4T),
lamivudine (3TC), and nelfinavir (NLF), plasma RNA copy
number again dropped below 50/ml and has remained less than
50/ml for an additional 41 months. Plasma HIV-1 RNA copy
number has remained ,50 copies/ml in all other infants.
Preservation of peripheral blood CD4 T cells following the
suppression of viral replication. Prior to the initiation of ther-
apy, the percentage of CD4 T cells in the peripheral blood of
the infants studied ranged from 14 to 63% (median, 44%)
(Table 1). The percentage of CD4 T cells in the peripheral
blood at baseline was normal for age in 14 infants and ,25%
in only 3 infants. At 48 weeks of therapy, the percentage of
CD4 T cells in the peripheral blood ranged from 29 to 59%
(median, 45%). The peripheral blood CD4 count therefore
normalized or remained normal for age in all infants following
the suppression of viral replication.
HIV-1 specific antibody responses following the initiation of
combination antiretroviral therapy. Following the initiation of
the combination antiretroviral therapies, a reduction in HIV-1
antibody titers was observed in all infants, and all but one
infant became seronegative by 16 months of age (Fig. 2). The
decline in antibody titers was accompanied by loss of antibody
binding in Western blot assays. The kinetics of plasma HIV-
1-specific antibody clearance in infants who received early
therapy are similar to those observed in uninfected infants
born to HIV-1-seropositive women (Fig. 2), suggesting that
these infants did not actively generate HIV-1-specific antibod-
ies. This was observed despite normal plasma immunoglobu-
lins for age (data not shown). By contrast, infants with persis-
tent viral replication maintained high titers of HIV-1-specific
antibodies in their peripheral blood.
HIV-1-specific antibodies were promptly detected by ELISA
and by Western blotting (gp160, gp120, p66, P55, p51, gp41,
p24, p17) in the plasma of the infant (P-3742) who experienced
viral breakthrough after 15 months of therapy (Fig. 1). Over
the subsequent 41 months following the resuppression of viral
replication, this child has remained seropositive by ELISA,
although decreased antibody binding in the ELISAs has been
observed. Antibody binding to only gp160, gp120, and p24 has
persisted on Western blotting. Altogether, these data suggest
that the generation of antibody responses is sensitive to the
presence of replicating virus. The decrease in the titers and
breadth of antibodies in infant P-3742 following the control of
viral replication also suggest that the maintenance of antibody
responses is sensitive to the presence of replicating virus.
HIV-1-specific lymphoproliferative responses following the
initiation of combination antiretroviral therapy. Sufficient
PBMC were available from 10 infants to evaluate HIV-1-spe-
cific lymphoproliferative responses (Table 2). Responses to
PWM and tetanus were detected in all infants. HIV-1 p24-
specific lymphoproliferative responses were detected at multi-
ple time points in one infant (P-3742 [Table 2]) following viral
breakthrough. HIV-1 p24-specific lymphoproliferative re-
sponses (SI 5 7 to 8) were also detected at one time point in
each of two additional infants but were not detected on sub-
sequent specimens. HIV-1 p24-specific lymphoproliferative re-
sponses were not detected (SI , 3) in the other seven infants.
HIV-1 gp160-specific lymphoproliferative responses were
not detected in any of the infants studied.
Longitudinal analyses of HIV-1-specific CTL responses.
Sufficient PBMC were available from eight infants to evaluate
HIV-1-specific CTL responses between 24 and 48 weeks fol-
lowing the initiation of therapy. Efforts to generate HIV-1-
specific CTL lines were made by culturing PBMC from serial
blood specimens obtained from each of six infants with psor-
alen-fixed B-LCL infected with vaccinia vectors expressing
HIV-1 gene products (16). Lytic activity of the CTL lines was
evaluated using 51Cr release assays. HIV-1-specific CTL re-
sponses to HIV-1 Gag and envelope were not detected in the
peripheral blood of any of the six infants studied in this manner.
In vitro stimulation has traditionally been used to detect and
quantify virus-specific CTL. It has long been recognized, how-
ever, that this method might underestimate CTL frequency
since it relies on sufficient propagation of cells in culture to the
point that they can be detected by the 51Cr release assay read-
out. A powerful and precise method that uses labeled major
histocompatibility complex-peptide complexes (tetramers) to
directly stain antigen-specific CD8 T cells in the peripheral
blood has recently been described (2). Serial PBMC specimens
from three HLA A*0201-positive infants with prolonged sup-
pression of HIV-1 replication were stained with HLA A*0201/
HIV-1 Gag p17 (LAI aa 77 to 85; SLYNTVATL) and RT
peptide (LAI aa 476 to 484; ILKEPVHGV) tetramers. Re-
sponses to these epitopes are commonly detected in the pe-
ripheral blood of individuals with the HLA A*0201 allele and
established HIV-1 infection (4); HLA A*0201/HIV-1 Gag p17
tetramer-staining cells have been detected in the circulation of
the majority of HIV-1-infected, HLA A*0201-positive adults
and children in our clinics. HIV-1-specific CD81 T cells were
not detected after direct tetramer staining (Fig. 3) of serial
PBMC specimens from any of these infants or after in vitro
peptide-specific stimulation of PBMC followed by tetramer
staining. One of these three infants was noted to be EBV
seropositive at 14 months of age. At weeks 56 and 80 of ther-
apy, PBMC were stained also stained with a tetramer repre-
senting an HLA A*0201-restricted, EBV lytic protein epitope
(BMLF1 aa 280 to 288/GLCTLVAML). Of note is that while
HIV-1-specific CD81 T lymphocytes were not detected in the
peripheral blood of this infant, EBV tetramer-staining cells
were detected at a frequency of 0.14% of PBMC (Fig. 4). The
detection of EBV tetramer-staining cells in the peripheral
blood suggests that this infant is capable of generating virus-
specific CTL in response to replicating virus.
Extrachromosomal HIV-1 infection intermediates. An im-
portant question in these studies is the extent to which viral
replication has been controlled in these infants. We have re-
cently shown that extrachromosomal HIV-1 infection interme-
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diates (2-LTR DNA circles) are labile products of HIV-1 rep-
lication and as such are indicative of recent infection events.
These replication intermediates have been used to detect on-
going viral replication in individuals on potent combination
antiretroviral therapy with plasma HIV-1 RNA levels below
the detection levels of currently available plasma viral RNA
assays (32). We therefore evaluated whether we could detect
2-LTR circle junctional sequences in PBMC infants from
our study cohort. While 2-LTR circle junctional sequences
were detected in the PBMC of three infants prior to therapy,
2-LTR circle sequences have not been detected in PBMC
obtained from any of these infants at multiple time points
after 48 weeks of therapy (e.g., Fig. 1). We then looked for
the presence of 2-LTR circles in PBMC obtained from five
additional infants at or after 48 weeks of therapy. In a
PBMC sample obtained from one infant (P-1238) after 48
weeks of therapy, a product of appropriate molecular size
was detected after 48 cycles in one of three replicate ampli-
fications of the specimen; identity of the product as a 2-LTR
circle junction was confirmed by sequencing. 2-LTR DNA
circle junction sequences were not detected in the PBMC of
any of the other four infants.
FIG. 1. Peripheral blood HIV-1 load and CD4 T-lymphocyte percentages (A and C) and HIV-1-specific immune responses (B and D) in two children (P-3743 [A
and B] and P-3742, [C and D]) with prolonged suppression of HIV-1 replication following early antiretroviral therapy.
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DISCUSSION
Recent studies have estimated the kinetics of HIV-1 repli-
cation in infected individuals and defined the central role of
HIV-1 replication in pathogenesis of HIV-1 infection (15, 21).
The present study was undertaken to evaluate the potential for
long-term suppression of viral replication following early ther-
apy of vertical infection and to determine the immune conse-
quences of such therapies.
Infants constitute an ideal population for studies investigat-
ing the virologic and immunologic consequences of early, po-
tent combination therapies. Since the vertical transmission of
HIV-1 from a woman to her infant is the predominant mode of
pediatric HIV-1 infection, infants at risk can be readily iden-
tified and evaluated for HIV-1 infection. Available data sug-
gest that the majority of infants acquire HIV-1 infection at
delivery (14). This, along with the ability to diagnose HIV-1
infection in the majority of infected infants within the first 4
weeks of life (20), allows the identification and therapy of
infants within days to weeks of acquiring infection.
In this cohort of infants who began antiretroviral therapy
within 3 months of birth, early combination therapy was asso-
ciated with a loss of plasma viremia and labile extrachromo-
somal replication intermediates. HIV-1 provirus has been per-
sistently detected in the PBMC of all infants. However, limited
availability of PBMC from these infants has precluded large-
scale virus cocultivation to evaluate the replication compe-
tence of the detected provirus. Despite apparently normal im-
mune systems, most infants did not develop persistent HIV-1-
specific immune responses. Altogether, our data suggest that
early, potent combination therapy may allow extremely strin-
gent, if not complete, control of viral replication.
The lack of persistently detectable HIV-1 specific immune
responses in these infants was surprising given the high levels
of plasma virus (median, 105.3 RNA copies/ml) that were de-
tected prior to therapy; in addition, plasma HIV-1 RNA was
detected in most infants by ultrasensitive assay for up to 68
weeks. Plasma RNA presumably represented replicating virus
and therefore should have served as an appropriate stimulus
for both humoral and cell-mediated immune responses; how-
ever, even a nonreplicating source of antigen should have
evoked antibody responses.
The lack of persistent HIV-1-specific immune responses in
infants contrasts with the persistent HIV-1-specific immune
responses reported in adults who receive combination antiviral
FIG. 2. HIV-1-specific antibodies measured by ELISA in plasma from in-
fants with durable (.48 weeks; n 5 15; A) or incomplete/transient (n 5 4; B)
suppression of HIV-1 replication following early antiretroviral therapy. HIV-1-
specific antibodies measured by ELISA in plasma from HIV-1-uninfected infants
born to HIV-1-infected women are depicted in panel C (n 5 5); HIV-1 anti-
bodies measured in the plasma of HIV-1-infected infants who did not receive
therapy over the first 12 months of life are depicted in panel D (n 5 4).
TABLE 2. HIV-1-specific lymphoproliferative responses in infants treated with early, potent combination therapy
Patient Age(mo)
Study
wk PWM Tetanus p24 gp160
P-1228 16 68 240 29 0.2 0.3
23 104 863 130 0 ND
26 116 153 80 1 ND
P-1048 7 32 75 2 2 1.6
11 48 250 6 1 0.5
P-1235 8 24 154 1 1 2
14 48 293 11 2 3
P-1238 8 24 486 1 0.7 1.7
15 48 157 32 1.1 1.8
18 68 305 150 1.2 0.7
21 80 143 35 0.5 0.5
P-1246 8 32 889 62 8 1.1
12 68 988 123 0 0
15 80 643 219 1.4 0.5
P-1247 7 24 64 32 7 1.7
18 68 188 24 1.4 1.1
P-1252 14 48 398 12 1.0 0.6
P-1222 8 24 158 6 0.6 1
P-3742 39 208 106 25 8 ,2
41 216 251 43 10 ,2
58 284 98 12 14 1
P-3743 35 192 22 6 ,2 ,2
40 212 393 19 ,2 ,2
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therapy within 3 to 4 months of acquisition of infection (22, 23,
25, 27, 30). Several investigators (22, 27, 30, 31) have reported
persistently detectable HIV-1-specific CD4 T-lymphocyte re-
sponses in adults who received combination therapy during
primary infection and have suggested that early, aggressive
treatment of primary infection may facilitate the generation of
these responses. While some groups have reported reduced
antibody (25) and CTL (23) responses in adults treated during
primary infection, the lack of persistently detectable responses
is unusual (8).
Clonal deletion of CD81 T cell responses in the presence of
very high levels of antigen has been previously reported in the
context of acute murine lymphocytic choriomeningitis virus
infection (26). At least two lines of evidence argue against
clonal deletion in our study population. First, the detection of
HIV-1-specific antibody and lymphoproliferative responses in
the peripheral blood of infant P-3742 following the break-
through in viral replication argues against clonal deletion of
HIV-1-reactive CD4 T lymphocytes. Additionally, the persis-
tent detection of antibody and CD8 T-lymphocyte-mediated,
HIV-1-specific CTL responses (4, 5, 18, 24, 28) in infants with
uncontrolled viral replication argues against this.
The paucity of persistently detectable HIV-1-specific im-
mune responses despite prolonged plasma viremia suggests
that there may be a period during which the generation of
immune responses is inefficient in infants. These data are com-
patible with prior data from our laboratory (18, 19, 28) and
others (11, 12) suggesting a reduced ability to generate virus-
FIG. 3. HLA Ap0201/Gag p17 tetramer staining of PBMC obtained prior to therapy (day 0) and at weeks 24 and 68 of therapy from an infant (P-1228) with durable
control of HIV-1 replication (.96 weeks) after initiating ZDV/3TC/NVP therapy at 1 month of age. An HLA Ap0201-restricted, epitope-specific CTL line derived from
an adult long-term nonprogressor was used as a positive control (53% of cells stained with tetramer; upper left).
FIG. 4. HLA Ap0201/HIV Gag p17, (A2-gag), HLA Ap0201/HIV RT (A2-pol), or HLA Ap0201/EBV BMLF1 (A2-EBV) tetramer staining of PBMC obtained at
56 weeks of therapy from HIV-1 infected, EBV-seropositive infant P-1252.
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specific immune responses in young infants. This might be due
to a reduced efficiency of antigen presentation by infant den-
dritic cells (particularly to naı¨ve T lymphocytes (33) or to a
diminished ability of infant lymphocytes to produce factors,
such as cytokines (36), important for the generation and main-
tenance of cell-mediated immunity. Suppression of viral repli-
cation during this period of relative immunological immaturity
might critically limit the priming and expansion of virus-spe-
cific immune responses.
The development of normal antibody and cell-mediated im-
mune responses to vaccine antigens (e.g., tetanus) or other
viral (e.g., EBV) infections in these infants suggests that HIV-
1-specific immune responses are particularly impaired. Factors
that could contribute to this include the acquisition of infection
in the presence of high titers of passively acquired, maternal
HIV-1-specific antibodies and/or the selective depletion of
HIV-1-specific CD4 T cells through the cytopathic effects of
the virus or other mechanisms. Studies to better understand
the factors that influence the generation of HIV-1-specific
immune responses in these infants are under way. These stud-
ies include assays that detect intracellular cytokines in CD4 T
lymphocytes by flow cytometry following in vitro stimulation,
which appear to be more sensitive than lymphoproliferative
assays for the detection of HIV-1-specific CD4 T-lymphocyte
responses (29; A. C. McNeil, W. L. Shupert, J. A. Mican, and
M. Connors, presented at the 7th Conference on Retroviruses
and Opportunistic Infections, San Francisco, Calif., 30 Janu-
ary–2 February 2000).
In summary, early, potent combination antiretroviral ther-
apy of HIV-1-infected infants allowed the long-term suppres-
sion of viral replication and preservation of immune function.
In contrast to what is typically seen in adults treated early,
persistent HIV-1-specific immune responses were not detected
in most infants. The absence of detectable, persistent HIV-1-
specific immune responses suggests that vaccine-induced,
HIV-specific immune responses may be helpful in further con-
trolling the virus early in life.
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